Thiopurine treatment in inflammatory bowel disease - Clinical pharmacology and implication of pharmacogenetically guided dosing

被引:124
作者
Teml, Alexander
Schaeffeler, Elke
Herrlinger, Klaus R.
Klotz, Ulrich
Schwab, Matthias
机构
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany
[2] Univ Tubingen, Dept Clin Pharmacol, Tubingen, Germany
[3] Robert Bosch Krankenhaus, Dept Gastroenterol Hepatol & Endocrinol, Stuttgart, Germany
关键词
D O I
10.2165/00003088-200746030-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This review summarises clinical pharmacological aspects of thiopurines in the treatment of chronic inflammatory bowel disease (IBD). Current knowledge of pharmacogenetically guided dosing is discussed for individualisation of thiopurine therapy, particularly to avoid severe adverse effects. Both azathiciprine and mercaptopurine are pro-drugs that undergo extensive metabolism. The catabolic enzyme thiopurine S-methyltransferase (TPMT) is polymorphically expressed, and currently 23 genetic variants have been described. On the basis of an excellent phenotype-genotype correlation for TPMT, genotyping has become a safe and reliable tool for determination of a patient's individual phenotype. Thiopurine-related adverse drug reactions are frequent, ranging from 5% up to 40%, in both a dose-dependent and -independent manner. IBD patients with low TPMT activity are at high risk of developing severe haematotoxicity if pharmacogenetically guided dosing is not performed. Based on several cost-benefit analyses, assessment of TPMT activity is recommended prior to thiopurine therapy in patients with IBD. The underlying mechanisms of azathioprine/mercaptopurine-related hepatotoxicity, pancreatitis and azathioprine intolerance are still unknown. Although the therapeutic response appears to be related to 6-thioguanine nucleotide (6-TGN) concentrations above a threshold of 230-260 pmol per 8 x 10(8) red blood cells, at present therapeutic drug monitoring of 6-TGN can be recommended only to estimate patients' compliance. Drug-drug interactions between azathioprine/mercaptopurine and aminosalicylates, diuretics, NSAIDs, warfarin and infliximab are discussed. The concomitant use of allopurinol without dosage adjustment of azathioprine/mercaptopurine leads to clinically relevant severe haematotoxicity due to elevated thiopurine levels. Several studies indicate that thiopurine therapy in IBD during pregnancy is safe. Thus, azathioprine/mercaptopurine should not be withdrawn in strictly indicated cases of pregnant IBD patients. However, breastfeeding is contraindicated during azathioprine/mercaptopurine therapy. Use of azathioprine/mercaptopurine for induction and maintenance of remission in corticosteroid-dependent or corticosteroid-refractory IBD, particularly Crohn's disease, is evidence based. To improve response rates in thiopurine therapy of IBD, comprehensive analyses including metabolic patterns and genome-wide profiling in patients with azathioprine/mercaptopurine treatment are required to identify novel candidate genes.
引用
收藏
页码:187 / 208
页数:22
相关论文
共 226 条
[1]   Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease [J].
Achkar, JP ;
Stevens, T ;
Easley, K ;
Brzezinski, A ;
Seidner, D ;
Lashner, B .
INFLAMMATORY BOWEL DISEASES, 2004, 10 (04) :339-345
[2]   Azathioprine-induced pure red cell aplasia: Case report and review [J].
Agrawal, A ;
Parrott, NR ;
Riad, HN ;
Augustine, T .
TRANSPLANTATION PROCEEDINGS, 2004, 36 (09) :2689-2691
[3]   ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression [J].
Allorge, D ;
Hamdan, R ;
Broly, F ;
Libersa, C ;
Colombel, JF .
GUT, 2005, 54 (04) :565-565
[4]   SAFETY OF AZATHIOPRINE IN PREGNANCY IN INFLAMMATORY BOWEL-DISEASE [J].
ALSTEAD, EM ;
RITCHIE, JK ;
LENNARDJONES, JE ;
FARTHING, MJG ;
CLARK, ML .
GASTROENTEROLOGY, 1990, 99 (02) :443-446
[5]   Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency [J].
Andersen, JB ;
Szumlanski, C ;
Weinshilboum, RM ;
Schmiegelow, K .
ACTA PAEDIATRICA, 1998, 87 (01) :108-111
[6]  
[Anonymous], COCHRANE DATABASE SY, DOI 10.1002/14651858.CD000545
[7]   Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease [J].
Ansari, A ;
Hassan, C ;
Duley, J ;
Marinaki, A ;
Shobowale-Bakre, EM ;
Seed, P ;
Meenan, J ;
Yim, A ;
Sanderson, J .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (10) :1743-1750
[8]   Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis [J].
Ardizzone, S ;
Maconi, G ;
Russo, A ;
Imbesi, V ;
Colombo, E ;
Porro, GB .
GUT, 2006, 55 (01) :47-53
[9]   Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease [J].
Ardizzone, S ;
Maconi, G ;
Sampietro, GM ;
Russo, A ;
Radice, E ;
Colombo, E ;
Imbesi, V ;
Molteni, M ;
Danelli, PG ;
Taschieri, AM ;
Porro, GB .
GASTROENTEROLOGY, 2004, 127 (03) :730-740
[10]   Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study [J].
Ardizzone, S ;
Bollani, S ;
Manzionna, G ;
Imbesi, V ;
Colombo, E ;
Porro, GB .
DIGESTIVE AND LIVER DISEASE, 2003, 35 (09) :619-627